Galera Therapeutics, Inc.
Reported to SECin USCIK 0001563577Filings at SEC EDGAR
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 15. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Sorensen MelPresident and CEO | Returned to the issuer | —30,000 shares | Aug 5, 2026 | Sorensen MelPresident and CEO | — | Returned to the issuer | 30,000 | Aug 5, 2026 |
| Sorensen MelPresident and CEO | Returned to the issuer | —975 shares | Aug 5, 2026 | Sorensen MelPresident and CEO | — | Returned to the issuer | 975 | Aug 5, 2026 |
| LOKAY KEVIN G— | Returned to the issuer | —240 shares | Aug 5, 2026 | LOKAY KEVIN G | — | Returned to the issuer | 240 | Aug 5, 2026 |
| CHANG NANCY T— | Returned to the issuer | —480 shares | Aug 5, 2026 | CHANG NANCY T | — | Returned to the issuer | 480 | Aug 5, 2026 |
| CHANG NANCY T— | Conversion | nothing paid661.309 shares | Aug 5, 2026 | CHANG NANCY T | nothing paid | Conversion | 661.309 | Aug 5, 2026 |